Fate Therapeutics, Inc.
FATEHealthcare|Biotechnology|US
$1.83
-0.01 (-0.81%)
Tangible Book / Share
$1.08
Cash / Share
$1.13
Clinical Trials (27)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07570862 A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis | Lupus Nephritis, Systemic Lupus Erythematosus | P2 | Recruiting | 53 | Open-label | FT819 |
| NCT07800871 FT839 in Autoimmune Diseases | ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | P1P2 | Recruiting | 446 | Open-label | FT839 |
| NCT04629729 FT819 in Subjects With B-cell Malignancies | Lymphoma, B-Cell, Chronic Lymphocytic Leukemia | P1 | Active | 54 | Open-label | FT819, Cyclophosphamide, Fludarabine, IL-2, Bendamustine |
| NCT07560865 First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma | Astrocytoma, Glioblastoma | P1 | Recruiting | 9 | Open-label | FT536 |
| NCT06308978 A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | P1 | Recruiting | 244 | Open-label | FT819, Fludarabine, Cyclophosphamide, Bendamustine |
| NCT06241456 FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors | Advanced Solid Tumor | P1 | Recruiting | 351 | Open-label | FT825, Fludarabine, Cyclophosphamide, Bendamustine, Docetaxel, Cisplatin, Cetuximab |
| NCT07216105 FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | Non-Small Cell Lung Cancer, Colorectal Cancer | P1 | Recruiting | 119 | Open-label | FT836, Cetuximab, Trastuzumab |
| NCT06877182 Novel Neuroradiological Workflow for the Assisted DIAgnosis and Management of DEMentia with Artificial Intelligence | Alzheimer Disease, Dementia | Active | 80,000 | — | — | |
| NCT01627314 The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies. | Hematologic Malignancies | P2 | Terminated | 62 | RCT, Open-label | ProHema-CB, Untreated CB |
| NCT02743351 Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | Hematologic Malignancies, Acute Myeloid Leukemia | P1P2 | Completed | 96 | RCT, Double-blind | ProTmune, Control Arm |
| NCT05182073 FT576 in Subjects With Multiple Myeloma | Multiple Myeloma, Myeloma | P1 | Completed | 31 | Open-label | FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine, Daratumumab, Bendamustine |
| NCT05069935 FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Solid Tumor, Adult | P1 | Terminated | 16 | Open-label | FT538, Cyclophosphamide, Fludarabine |
| NCT01527838 Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease | P1 | Completed | 10 | Open-label | Single FT1050 treated UCB unit |
| NCT04023071 FT516 in Subjects With Advanced Hematologic Malignancies | Acute Myelogenous Leukemia, B-cell Lymphoma | P1 | Terminated | 72 | Open-label | FT516, Rituximab, Obinutuzumab, Cyclophosphamide, Fludarabine, IL-2, Bendamustine |
| NCT00890500 Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. | Hematologic Malignancies, Allogeneic Stem Cell Transplantation | P1 | Completed | 12 | Open-label | Fludarabine, Melphalan, Antithymocyte Globulin, Sirolimus, Tacrolimus |
| NCT05950334 FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) | Relapsed/Refractory B-Cell Lymphoma | P1 | Completed | 20 | Open-label | FT522, Rituximab, Cyclophosphamide, Fludarabine, Bendamustine |
| NCT02354443 A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders | Metabolic Disorders | P1 | Terminated | 1 | Open-label | ProHema-CB Transplant |
| NCT04614636 FT538 in Subjects With Advanced Hematologic Malignancies | Acute Myeloid Leukemia, AML, Adult | P1 | Terminated | 42 | Open-label | FT538, Cyclophosphamide, Fludarabine, Daratumumab, Elotuzumab |
| NCT05934097 FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma | P1 | Withdrawn | — | Open-label | FT596, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab, Bendamustine |
| NCT03319459 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | HER2 Positive Gastric Cancer, Colorectal Cancer | P1 | Completed | 44 | Open-label | FATE-NK100, Cetuximab, Trastuzumab |
| NCT04245722 FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | Lymphoma, B-Cell, Chronic Lymphocytic Leukemia | P1 | Terminated | 98 | Open-label | FT596, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab, Bendamustine |
| NCT03841110 FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | Advanced Solid Tumors, Lymphoma | P1 | Completed | 37 | Open-label | FT500, Nivolumab, Pembrolizumab, Atezolizumab, Cyclophosphamide, Fludarabine, IL-2 |
| NCT05395052 FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Non Small Cell Lung Cancer, Colorectal Cancer | P1 | Terminated | 5 | Open-label | FT536, Cyclophosphamide, Fludarabine, IL-2, IL-2 |
| NCT04551885 FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Solid Tumor, Adult | P1 | Terminated | 12 | Open-label | FT516, Avelumab, Cyclophosphamide, Fludarabine, IL-2 |
| NCT02354417 A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies | Hematologic Malignancies | P1 | Terminated | 3 | Open-label | Biological: ProHema-CB |
| NCT04093622 Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy | Hematological Malignancy | Terminated | 2 | — | — | |
| NCT04106167 Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | Advanced Solid Tumor, Lymphoma | Terminated | 20 | — | — |